JSSH
CYTK icon

J. Safra Sarasin Holding’s Cytokinetics CYTK Stock Holding History

J. Safra Sarasin Holding’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.55M Buy
18,211
+9,577
+111% +$688K 0.02% 308
2026
Q1 		$569K Sell
8,634
-14,736
-63% -$937K 0.01% 393
2025
Q4 		$1.48M Sell
23,370
-1,097
-4% -$68.2K 0.02% 234
2025
Q3 		$1.34M Sell
24,467
-43,723
-64% -$1.8M 0.02% 257
2025
Q2 		$2.25M Buy
68,190
+40,399
+145% +$1.41M 0.04% 202
2025
Q1 		$1.12M Buy
27,791
+14,764
+113% +$679K 0.02% 301
2024
Q4 		$613K Buy
+13,027
New +$677K 0.01% 392

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

J. Safra Sarasin Holding's CYTK Position: Q2 2026 in Review

J. Safra Sarasin Holding increased its Cytokinetics (CYTK) stake by 111% in Q2 2026, buying an estimated $688K and bringing the position to 18,211 shares worth $1.55M. The position accounts for 0.02% of the portfolio, ranked #308.

J. Safra Sarasin Holding first reported a position in CYTK in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.25M in Q2 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • J. Safra Sarasin Holding held 18,211 shares of Cytokinetics worth $1.55M as of Q2 2026.
  • J. Safra Sarasin Holding bought 9,577 Cytokinetics shares in Q2 2026, an estimated $688K.
  • Cytokinetics made up 0.02% of J. Safra Sarasin Holding's portfolio in Q2 2026, its #308 holding.
  • J. Safra Sarasin Holding first reported a position in Cytokinetics in Q4 2024 and has held it in 7 quarters since.
  • J. Safra Sarasin Holding's Cytokinetics position peaked at $2.25M in Q2 2025.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on J. Safra Sarasin Holding's 13F filing for Q2 2026, filed 31 Jul 2026.